Drug
Arformoterol
Arformoterol: highest development phase Post-Market, developed by Sumitomo Pharma, United Therapeutics. 3 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Sumitomo Pharma, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Arformoterol tartrate NCT00754546 | Post-Market | Chronic Obstructive Pulmonary Disease |
| Arformoterol NCT00909779 | Phase 3 | Chronic Obstructive Pulmonary Disease |
| arformoterol NCT01391559 | Not Applicable | Chronic Obstructive Pulmonary Disease |
Latest
No recent events.
Follow Arformoterol on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.